Description
PrymaLab · Research use only
Tirzepatide 15mg
15 mg of tirzepatide, a GIP and GLP-1 receptor agonist, as lyophilized powder
Tirzepatide (LY3298176, CAS 2023788-19-2) is an acylated 39-residue peptide designed to activate the receptors for two gut hormones, GIP and GLP-1. Here it comes as a 15 mg fill of freeze-dried powder, one and a half times the 10 mg main vial, in a crimp-sealed glass vial. Research on it covers receptor pharmacology, molecular structure and phase 3 trials in type 2 diabetes.
Specifications
| Property | Value |
|---|---|
| Compound | Tirzepatide LY3298176; GIP/GLP-1 receptor dual agonist |
| CAS number | 2023788-19-2 |
| Molecular formula | C225H348N48O68 |
| Theoretical mass | 4813.5 Da |
| Sequence / structure | H-Y-Aib-EGTFTSDYSI-Aib-LDKIAQK(2×AEEA-γGlu-C20 diacid)AFVQWLIAGGPSSGAPPPS-NH₂ (39 residues; Aib2 and Aib13; Lys20 acylated with eicosanedioic acid via γ-Glu and two AEEA spacers; C-terminal amide) |
| Label claim | 15 mg/vial |
| Form | Lyophilized (freeze-dried) powder or cake in a sealed glass vial with a rubber stopper and aluminium crimp cap |
| Storage, sealed | −20 °C, desiccated, dark |
| Purity specification | 99.0% or higher by RP-HPLC |
| Lot certificate | Results for the lot now shipping are in the certificate panel on this page |
| Safety data sheet | PL-SDS-173 |
Other fills
This is the 15 mg fill. The Tirzepatide 10mg page is the main listing for this compound, with the full research summary and every fill side by side. Other fills: 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 80 mg, 100 mg.
What the research covers
GIP and GLP-1 act through incretin receptors that regulate carbohydrate metabolism, and tirzepatide is an agonist at both1. Sun and colleagues reported that it activates the GIP receptor much as native GIP does, but that its action at the GLP-1 receptor departs markedly from GLP-1’s and causes less desensitisation1. That was structural work on receptor complexes, carried out by cryogenic electron microscopy and simulation. The signalling studies and trial data are summarised on the Tirzepatide 10 mg page.
The Retatrutide vs Tirzepatide guide covers the literature in more depth.
How each lot is tested
Every lot is tested in PrymaLab’s own laboratory in Ashland, Kentucky before release: RP-HPLC for purity, LC-MS for identity, Karl Fischer titration for water, LAL for endotoxin and USP <71> for sterility. The results for the lot now shipping are in the certificate panel on this page, and the certificate number, key and QR code can be checked on the verify page. These are in-house results from PrymaLab Analytical, not an independent test, and the lab is not accredited to ISO 17025. The third-party testing guarantee on this page still applies: if any independent laboratory finds the wrong compound, or less than the stated purity or amount, the order is refunded and the cost of the test is reimbursed.
Frequently asked questions
Is the 15 mg fill a different form of tirzepatide?
No. It is the same acylated 39-residue peptide as every other fill, with a theoretical mass of 4813.5 Da. Only the quantity changes: about 3.12 µmol here, from a separate lot with a certificate of its own.
Where is the certificate for this vial?
The lot number on the label identifies it. The panel on this page shows the lot now shipping, with purity, identity, water, endotoxin and sterility results, and the verify page checks a certificate by number and key.
References
- Sun B, Willard FS, Feng D, et al. Structural determinants of dual incretin receptor agonism by tirzepatide. Proc Natl Acad Sci U S A. 2022;119(13):e2116506119. DOI · PubMed
Research use only
For laboratory research use only. Tirzepatide 15mg is not a drug, food, cosmetic or dietary supplement, is not approved by the FDA or any comparable authority for human or veterinary use, and must not be given to people or animals. It is sold to qualified researchers and institutions, and the buyer is responsible for lawful handling and disposal.
Reviews
There are no reviews yet.